Ernexa Therapeutics Inc. (ERNA) Non-Current Deffered Revenue (2010 - 2024)

Ernexa Therapeutics (ERNA) has 13 years of Non-Current Deffered Revenue data on file, last reported at $298000.0 in Q2 2024.

• Quarterly Non-Current Deffered Revenue rose 19.2% year-over-year to $298000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $298000.0 (up 19.2% YoY) and the FY2023 annual result came in at $392000.0, changed N/A from the prior year.
• Non-Current Deffered Revenue eased to $298000.0 in Q2 2024, from $345000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $392000.0 in Q4 2023 to a low of $1000.0 in Q1 2020.
• A 3-year average of $223500.0 and a median of $250000.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue plunged 95.65% — and 2024, when it soared 38.0%.
• Tracing ERNA's Non-Current Deffered Revenue over 3 years: stood at $2000.0 in 2020, then soared by 19500.0% to $392000.0 in 2023, then dropped by 23.98% to $298000.0 in 2024.
• The last three Non-Current Deffered Revenue figures came in at $298000.0 (Q2 2024), $345000.0 (Q1 2024), and $392000.0 (Q4 2023), per Business Quant data.